Santen Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santen Pharmaceutical Co., Ltd.
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
Brainsgate’s ISS500 can reportedly lessen stroke symptoms if put into use within 24 hours of the onset of symptoms.
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
- Generic Drugs
- OTC, Consumer
- Implantable Devices
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Eyevance Pharmaceuticals LLC.
- Novagali Pharma SA
- Santen Inc.
- Chongqing Santen Kerui Pharmaceutical Co., Ltd
- InnFocus Inc,